These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21209236)

  • 1. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
    Garraffo R; Lavrut T; Ferrando S; Durant J; Rouyrre N; MacGregor TR; Sabo JP; Dellamonica P
    J Clin Pharmacol; 2011 Jul; 51(7):1071-8. PubMed ID: 21209236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
    MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
    HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
    Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F; Scholl P; Huang DB; MacGregor TR; Vinisko R; Castles MA; Berger F; Robinson P
    J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
    la Porte CJ; Sabo JP; Béïque L; Cameron DW
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
    Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
    Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
    Pham PA; la Porte CJ; Lee LS; van Heeswijk R; Sabo JP; Elgadi MM; Piliero PJ; Barditch-Crovo P; Fuchs E; Flexner C; Cameron DW
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4385-92. PubMed ID: 19667285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
    Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
    Sekar VJ; Lefebvre E; De Marez T; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Drugs R D; 2007; 8(4):241-8. PubMed ID: 17596110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
    Hanley WD; Wenning LA; Moreau A; Kost JT; Mangin E; Shamp T; Stone JA; Gottesdiener KM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2752-5. PubMed ID: 19398643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
    Mehandru S; Markowitz M
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1821-8. PubMed ID: 14585057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.
    McCallister S; Valdez H; Curry K; MacGregor T; Borin M; Freimuth W; Wang Y; Mayers DL
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):376-82. PubMed ID: 15097154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
    la Porte CJ; Sabo JP; Elgadi M; Cameron DW
    Antimicrob Agents Chemother; 2009 Jan; 53(1):162-73. PubMed ID: 19015362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.